<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi> is a hypomethylating agent </plain></SENT>
<SENT sid="1" pm="."><plain>Its action in DNA leads to the reactivation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor genes and the subsequent differentiation of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>In a randomised, phase III trial in patients (n = 170) with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), intravenous <z:chebi fb="0" ids="50131">decitabine</z:chebi> (45 mg/m(2)/day for 3 consecutive days every 6 weeks) combined with supportive care achieved a higher response rate (including eight complete and seven partial responses) than supportive care alone, which achieved no responses (17% vs 0%; p &lt; 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>The median times to response and duration of response were 3.3 and 10.3 months in the phase III trial </plain></SENT>
<SENT sid="4" pm="."><plain>In three phase II studies in patients (n = 29-87) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> treated with <z:chebi fb="0" ids="50131">decitabine</z:chebi> (40 or 50 mg/m(2)/day for 3 days every 5-6 weeks), the percentage of patients achieving a complete or partial response or an improvement ranged from 26% to 49%, and the median duration of response or improvement ranged from 4.9 to 8.3 months </plain></SENT>
<SENT sid="5" pm="."><plain>The main adverse event associated with <z:chebi fb="0" ids="50131">decitabine</z:chebi> is <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
</text></document>